Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

NCT04466904 · Completed

Last updated 2026-05-28

This clinical trial tests the safety and tolerability of multiple doses of the drug IBI362 compared to a placebo in Chinese adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 42 people

Who can join Ages 18–75 · all sexes

Timeline Started 2020-09 · est. completion 2021-05

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT04466904 ↗

Description as written by the study sponsor.

This trial is aimed to investigate the safety, tolerability, PK and PD of multiple subcutaneous injections of IBI362 in Chinese patients with type 2 diabetes who have poor glycemic control after lifestyle or metformin intervention

Treatments tested

IBI362 Drug

Administrated by subcutaneous injection
Placebo Drug

Administrated by subcutaneous injection
Dulaglutide Drug

Administrated by subcutaneous injection

Main thing measured	To assess the number and incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of IBI362 compared with placebo
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04466904 ↗